Company Profile

Nexgenia Inc
Profile last edited on: 1/27/17      CAGE: 6BAK4      UEI:

Business Identifier: Proprietary reagents for molecular and cell separations: enable efficient, low cost, gentler separations of cells in blood.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4000 Mason Road Fluke Hall Suite 308d
Seattle, WA 98195
   (206) 616-1097
Location: Single
Congr. District: 07
County: King

Public Profile

Based on proprietary technology licensed from University of Washington, NNexgenia develops and manufactures proprietary stimuli-responsive polymers and polymer-containing magnetic nanoparticles. These unique polymers change state – from soluble single macromolecules to large insoluble aggregates – in response to very modest changes (i.e., temperature, pH, salt) in their environment. When these polymers are attached to other chemicals / biologicals, they confer the same environmentally-responsive characteristics. Thus the resulting combinations can be small when it is advantageous to be small and large when that facilitates separation and analysis. This property enables the development of faster, more complete molecular / cellular separations and faster, more sensitive immunoassays. Nexgenia will sell these reagents to companies for use in their products or manufacturing. A particular focus is working with biotechnology companies to enable separation and isolatation of cells in the most efficient cost-effective manner possibl

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $232,149
Project Title: Stimuli-Responsive Reagents for Improved Cell Isolations and Activations
2014 2 NIH $1,317,016
Project Title: Smart Polymer Reagents for Sensitivity and Speed-Enhanced Clinical Diagnostics

Key People / Management

  Ron Myers -- CEO

  Thomas Schulte -- President

  Barrett J Nehilla

  Nicole Provost -- Chief Scientific Officer